SHR-2004

Unknown / undisclosed

Phase 3complete

Evidence outlook · registrational

Venous Thromboembolism: registrational trials complete

Its supporting mid-stage studies have completed. Its registrational studies have completed. Check News and the registry record for topline outcomes.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Venous Thromboembolism
NCT06825416 · Beijing Suncadia Pharmaceuticals Co., Ltd
2025-03-16 – 2026-04-23 · Prevention of Arterial and Venous Thrombosis
What this study did
Phase 2 (2)
Venous Thromboembolism
NCT06220123 · Beijing Suncadia Pharmaceuticals Co., Ltd
2024-02-16 – 2024-12-31 · Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
What this study did
NCT05752461 · Beijing Suncadia Pharmaceuticals Co., Ltd
2023-04-12 – 2024-06-25 · Prevention of Venous Thromboembolism After Knee Arthroplasty
What this study did
Phase 1 (2)
Other / comorbidity
NCT06280768 · Beijing Suncadia Pharmaceuticals Co., Ltd
2024-04-10 – 2025-01-10 · Atrial Fibrillation
What this study did
NCT05369767 · Beijing Suncadia Pharmaceuticals Co., Ltd
2022-05-24 – 2023-01-30 · Prevention of Arterial and Venous Thrombosis
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Venous Thromboembolism: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR-2004: this drugPhase 3UndisclosedFactor XInot yet gradedNo reviewed efficacy summary in this indication
CenvacibartPhase 3Monoclonal antibodyFactor XInot yet gradedNo reviewed efficacy summary in this indication
Gruticibart
Phase 2(overall)
Monoclonal antibodyFactor XI
Partial signal(overall)
No reviewed efficacy summary in this indication
SRSD107Phase 2RNA / oligonucleotideFactor XInot yet gradedNo reviewed efficacy summary in this indication
Amrecibart
Phase 1(overall)
Monoclonal antibodyFactor XI
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.